Tax expenses hurt Lupin's profit in FY12, but sales up 22% on growth in core markets
This article was originally published in Scrip
Executive Summary
Lupin has reported a 22% increase in net sales to Rs69.59 billion ($1.29 billion) for the year ended March 2012 backed by strong growth across its key geographies of the US, Japan and India, but tax expenses took the sheen off profits during the year. Net profits increased marginally to Rs8.67 billion as compared with Rs8.62 billion, largely due to a 168.3% increase in tax outflows to Rs3.08 billion on account of an increase in effective tax rates and tax on inventories shipped to overseas subsidiaries for new launches. Profits in the last quarter declined by 31% to Rs1.56 billion on account of tax expenses.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.